Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Navidea Biopharmaceuticals (NYSEMKT: NAVB ) , a developer of medical diagnostics and radiopharmaceutical agents, jumped as much as 20% after announcing that the Food and Drug Administration had granted Lymphoseek the fast track designation for sentinel lymph node detection in patients with head and neck cancer.
So what: The fast track designation is a tool the FDA uses that can sometimes speed along the review process for drugs or devices which target a specific unmet medical need. At the moment, there are no lymph node staging devices capable of assisting treatment diagnoses for head and neck cancer, so the designation appears logical. In clinical trials, Lymphoseek correctly identified 38 of 39 patients with pathology-positive lymph nodes, meeting its primary endpoint of a low false-negative rate.
Now what: I've been saying it for a while now, and it bears repeating again: Lymphoseek is an exciting product, and Navidea could be quite the bargain if it gains this supplemental new drug approval for its lead radiopharmaceutical agent. I suspect that the next decade of cancer treatment is going to strongly focus on personalization rather than more potent medications. That means perfecting the diagnostic tools to help patients and doctors determine a best course of treatment. I would certainly suggest adding it to your watchlist.
Don't miss out on this other incredible growth opportunity
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.